KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q1 2025 value amounting to $40.0 million.

  • Rigel Pharmaceuticals' Other Non-Current Liabilities changed 0.25% to $40.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $40.0 million, marking a year-over-year change of 0.25%. This contributed to the annual value of $40.0 million for FY2024, which is 9.26% up from last year.
  • Rigel Pharmaceuticals' Other Non-Current Liabilities amounted to $40.0 million in Q1 2025, which was down 0.25% from $40.0 million recorded in Q4 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' Other Non-Current Liabilities peaked at $57.5 million during Q1 2021, and registered a low of $38.8 million during Q3 2023.
  • For the 5-year period, Rigel Pharmaceuticals' Other Non-Current Liabilities averaged around $45.0 million, with its median value being $42.1 million (2023).
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Other Non-Current Liabilities surged by 105066.0% in 2021, and later plummeted by 2093.64% in 2023.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Other Non-Current Liabilities stood at $52.7 million in 2021, then fell by 19.84% to $42.3 million in 2022, then decreased by 5.49% to $39.9 million in 2023, then rose by 0.09% to $40.0 million in 2024, then changed by 0.0% to $40.0 million in 2025.
  • Its last three reported values are $40.0 million in Q1 2025, $40.0 million for Q4 2024, and $40.0 million during Q3 2024.